| Estonia | Russia | South Africa | Peru | China | Philippines | India |
---|---|---|---|---|---|---|---|
Cohort | |||||||
 Populationa, cases (n) | 38 | 6,537 | 6,494 | 564 | 826 | 11 | 20,763 |
Hospitalization costs (at 100% hospitalization), US$ totalb/per patientc | |||||||
 Bedaquiline + BR | 2,515,318/66,193 | 400,933,524/61,333 | 85,584,735/13,179 | 8,505,448/15,080 | 7,792,452/9,434 | 35,660/3,242 | 4,892,107/236 |
 BR only | 3,780,243/99,480 | 596,419,985/91,238 | 129,930,717/20,008 | 12,699,038/22,516 | 11,177,776/13,532 | 52,799/4,800 | 7,376,327/355 |
Outpatient care, US$ totalb/per patientc | |||||||
 Bedaquiline + BR | 23,858/628 | 1,716,115/263 | 1,221,043/188 | 47,999/85 | 77,975/94 | 394/36 | 1,740,459/84 |
 BR only | 17,667/465 | 1,109,759/170 | 1,144 148/20,008 | 31,283/55 | 72,985/88 | 249/23 | 1,979,948/95 |
Monitoring costs, US$ totalb/per patientc | |||||||
 Bedaquiline + BR | 66,887/1,760 | 11,449,710/1,752 | 7,778,834/1,198 | 721,800/1,280 | 930,012/1,126 | 9,182/835 | 15,202,670/732 |
 BR only | 69,860/1,838 | 10,165,718/1,555 | 6,808,367/1,048 | 682,575/1,210 | 1,019,445/1,234 | 8,989/817 | 16,650,529/802 |
Total healthcare costs (excluding treatment acquisition costs), US$ totalb/per patientc | |||||||
 Bedaquiline + BR | 2,606,062/68,581 | 414,099,348/63,347 | 94,584,612/14,565 | 9,275,248/16,445 | 8,800,439/10,654 | 45,236/4,112 | 21,835,236/1,052 |
 BR only | 3,867,769/101,783 | 607,695,462/92,962 | 137,883,232/21,232 | 13,412,896/23,782 | 12,270,205/14,855 | 62,037/5,640 | 26,006,804/1,253 |
 Incremental health care cost-savings (excluding acquisition costs) (bedaquiline + BR vs. BR), US$ totalb/per patientc | 1,261,707/33,202 | 193,596,114/29,615 | 43,298,620/6,667 | 4,137,648/7,337 | 3,469,766/4,201 | 16,801/1,528 | 4,171,568/201 |